Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondylitis (AS)

10 juni 2015 bijgewerkt door: AbbVie (prior sponsor, Abbott)

Safety and Effectiveness of Adalimumab in Patients With Ankylosing Spondylitis in Routine Clinical Practice

The research question explored in this study was whether the effectiveness and safety of adalimumab in participants with ankylosing spondylitis was maintained during long-term therapy in routine clinical practice in Germany.

Studie Overzicht

Toestand

Voltooid

Conditie

Gedetailleerde beschrijving

This was a postmarketing observational study (PMOS) for participants with insufficiently controlled, moderate to severe, active AS who were eligible for adalimumab therapy. Participants started treatment with adalimumab under normal clinical settings in Germany. Enrolled participants were followed during adalimumab therapy . Participants were assessed during regular clinic visits for up to 24 months and 359 clinicians (rheumatologists/orthopedists/general practitioners/internist) participated in the study. Since this was an observational trial, not all doctors followed the stated age limitations and some participants under the age of 18 were enrolled.

Studietype

Observationeel

Inschrijving (Werkelijk)

4681

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Participants with AS in routine clinical practice.

Beschrijving

Inclusion Criteria:

  1. Participants with active, AS for at least 4 weeks (BASDAI greater than or equal to 4).
  2. Participants who failed treatment with two non-steroidal anti-inflammatory drugs (NSAIDs).
  3. No contraindications for anti-tumor necrosis factors (TNF) therapy.

Exclusion Criteria:

1. Participants who do not meet the above listed inclusion criteria.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: Case-Alleen
  • Tijdsperspectieven: Prospectief

Cohorten en interventies

Groep / Cohort
Ankylosing spondylitis
Participants with ankylosing spondylitis

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Mean Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score
Tijdsspanne: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
The BASDAI was a six question, participant-reported measure of overall disease activity that probed the level of fatigue, neck/back/hip pain, peripheral joint swelling and pain, localized tenderness, as well as morning stiffness severity and duration. It was scored on a numerical rating scale that ranged from 0 (no symptoms) to 10 (severe symptoms), and the minimum clinically important difference (MCID) was 1.0. The final BASDAI score was calculated using the following equation, in which 01 - 06 represents the question number: (BASDAI01 + BASDAI02 + BASDAI03 + BASDAI04 + BASDAI05/2 + BASDAI06*1.25/2)/5. The scale for question 6 was reduced to 0-8 since BASDAI06 was multiplied by 1.25. Data are reported as the mean change total score from baseline (Month 0).
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Mean Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score
Tijdsspanne: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
The BASFI was a ten question, participant-reported measure that evaluated physical function. Each question was scored on a numerical rating scale that ranged from 0 (no functional impairment) to 10 (maximal impairment), and the MCID was 0.7. The mean of the ten questions was the total BASFI score. Data are reported as the mean change of total score from baseline (Month 0).
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Number of Participants With Drug-Related Adverse Events (AEs)
Tijdsspanne: From signing of informed consent up to 24 months
An adverse event/adverse experience was any reaction, side effect or other untoward event associated with the use of a drug in humans, whether or not the event was considered drug related. This included adverse events occurring from accidental or deliberate drug overdose, from drug abuse, or from drug withdrawal. Exacerbations of pre-existing conditions are also considered adverse events. Data presented are adverse events that are drug-related and are detailed in the adverse event section of this report.
From signing of informed consent up to 24 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Mean Number of Involved Peripheral Joints
Tijdsspanne: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Peripheral joints were assessed by Tender Joint Counts (TJC) and Swollen Joint Counts (SJC), using pressure and joint manipulation during physical examination. Seventy-eight TJC and 76 SJC were evaluated and a score of 0 (not tender or swollen) or 1 (tender or swollen) was assigned for each joint with a higher total score indicating a greater number of involved joints.
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Percentage of Participants With Extraspinal Manifestations
Tijdsspanne: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Extraspinal manifestations (enthesitis, dactylitis, uveitis, psoriasis, and Inflammatory Bowel Disease (IBD)) were assessed by investigators and reported on the basis of their clinical evaluation and participant records.
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Mean Erythrocyte Sedimentation Rate (ESR)
Tijdsspanne: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Plasma concentrations of ESR were assessed as a marker of systemic inflammation that provided insights into the overall anti-inflammatory effect of rheumatologic therapies.
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Mean Plasma Concentrations of C-Reactive Protein (CRP)
Tijdsspanne: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Plasma concentrations of CRP were assessed as a marker of systemic inflammation that provided insights into the overall anti-inflammatory effect of rheumatologic therapies.
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Mean Bath Ankylosing Spondylitis-Global (BAS-G) Score
Tijdsspanne: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
The BAS-G was a participant-reported instrument with two items. In the first item, the participant rated the effect of their disease over the last week, and in the second item, the participant rated the effect of their disease over the previous 6 months. Each item of the BAS-G was scored on a scale ranging from 0 (no effect) to 10 (very severe effect). The mean of the two scores was the total BAS-G score and the MCID was 1.5.
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Mean Global Assessment of Disease Activity Score
Tijdsspanne: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Global Assessment of Disease Activity was a participant-reported measure that evaluated disease activity. It was scored on a scale that ranged from 0 to 10; lower scores indicated better patient status.
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Mean Participant Fatigue Score
Tijdsspanne: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Using the BASDAI questionnaire, participants assessed the overall level of fatigue/tiredness experienced by him/her. It was scored on a numerical rating scale from 0 (no symptoms) to 10 (severe symptoms).
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Mean Participant Pain Score
Tijdsspanne: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Using the BASDAI questionnaire, participants assessed the overall level of AS neck, back or hip pain experienced by him/her. It was scored on a numerical rating scale from 0 (no symptoms) to 10 (severe symptoms).
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Percentage of Participants With Morning Stiffness
Tijdsspanne: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Morning stiffness was a participant-reported assessment. The number of participants with morning stiffness were assessed at each visit.
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Mean Duration of Morning Stiffness
Tijdsspanne: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Participants accessed the duration of morning stiffness in 15 minute intervals from 0 to 2 hours. Data are reported as the mean duration of morning stiffness ± standard deviation.
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Percentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS) Improvement Criteria
Tijdsspanne: At 3, 6, 9, 12, 18, and 24 months
This is a four domain (participant global assessment of disease activity, assessment of spinal pain, assessment of function (BASFI), and assessment of duration/severity of morning stiffness (mean of BASDAI questions 5 and 6)), participant-reported assessment scored on a scale from 0 (best) to 10 (worst). To qualify for a 20% improvement, participants were required to have an improvement of greater than or equal to 20% and greater than or equal to 1 unit in at least 3 domains, and no worsening of greater than or equal to 20% and greater than or equal to 1 unit in the remaining domain. To achieve a 40% improvement, participants were required to have an improvement of greater than or equal to 40% and greater than or equal to 2 units in at least 3 domains, and no worsening at all in the remaining domain.
At 3, 6, 9, 12, 18, and 24 months
Percentage of Participants Achieving ASAS Partial Remission Criteria
Tijdsspanne: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
This is a four domain (participant global assessment of disease activity, assessment of spinal pain, assessment of function (BASFI), and assessment of duration/severity of morning stiffness (mean of BASDAI questions 5 and 6)), participant-reported assessment scored on a scale from 0 (best) to 10 (worst). To qualify for a partial remission, participants had to have values of 2 or less (on a scale of 10) in each of the 4 domains.
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Percentage of Participants With Impairment in Daily Activities During the Last 4 Weeks
Tijdsspanne: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
The impairment of daily activities was based on participant recall of events that occurred over the 4 weeks before the visit. Percentage of participants with impairment for 0, less than 7, 7 to 14, and greater than 14 days was assessed.
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Percentage of Participants Who Missed Work Days Due to Ankylosing Spondylitis (AS) in the Previous 12 Months
Tijdsspanne: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Mean Missed Work Days Due to Ankylosing Spondylitis in the Previous 12 Months
Tijdsspanne: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Percentage of Participants With In-Patient Hospitalization Due to Ankylosing Spondylitis in the Previous 12 Months
Tijdsspanne: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Mean Days of In-Patient Hospitalization Due to Ankylosing Spondylitis in the Previous 12 Months
Tijdsspanne: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Percentage of Participants on Adalimumab Monotherapy
Tijdsspanne: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Percentage of Participants With Concomitant Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)
Tijdsspanne: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Percentage of Participants With Concomitant Pain Relief/Anti-Inflammatory Agents
Tijdsspanne: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Participants with concomitant pain relief/anti-inflammatory agents like analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 (COX-2) inhibitors, and systemic glucocorticoids were assessed during the study period.
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Mean Equivalent Dose of Prednisolone
Tijdsspanne: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
The mean equivalent dose of prednisolone was calculated based on the International Standard for comparison of different glucocorticoid products.
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

AbbVie (prior sponsor, Abbott)

Onderzoekers

  • Studie directeur: Bianca Wittig, MD, AbbVie Deutschland GmbH & Co. KG, Medical Department

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Nuttige links

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start

1 januari 2006

Primaire voltooiing (Werkelijk)

1 mei 2014

Studie voltooiing (Werkelijk)

1 mei 2014

Studieregistratiedata

Eerst ingediend

1 maart 2010

Eerst ingediend dat voldeed aan de QC-criteria

2 maart 2010

Eerst geplaatst (Schatting)

3 maart 2010

Updates van studierecords

Laatste update geplaatst (Schatting)

9 juli 2015

Laatste update ingediend die voldeed aan QC-criteria

10 juni 2015

Laatst geverifieerd

1 juni 2015

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • P10-147

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Klinische onderzoeken op Spondylitis ankylopoetica

Zoek naar vergelijkbare onderzoeken

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

CROs by country

CROs in Congo

Voorwaarden

Zeldzame ziekten

Geneesmiddelinterventies

Voedingssupplementen

Sponsor / medewerkers

Locaties

3
Abonneren